BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas

Show full item record



Permalink

http://hdl.handle.net/10138/303863

Citation

Manninen , A A , Gardberg , M , Juteau , S , Ilmonen , S , Jukonen , J , Andersson , N & Carpen , O 2019 , ' BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas ' , PLoS One , vol. 14 , no. 4 , 0216043 . https://doi.org/10.1371/journal.pone.0216043

Title: BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas
Author: Manninen, Atte A.; Gardberg, Maria; Juteau, Susanna; Ilmonen, Suvi; Jukonen, Joonas; Andersson, Noora; Carpen, Olli
Contributor: University of Helsinki, Plastiikkakirurgian yksikkö
University of Helsinki, HUSLAB
University of Helsinki, HUS Musculoskeletal and Plastic Surgery
University of Helsinki, CAN-PRO - Translational Cancer Medicine Program
University of Helsinki, Department of Pathology
University of Helsinki, Precision Cancer Pathology
Date: 2019-04-30
Language: eng
Number of pages: 13
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/303863
Abstract: Background Sentinel node biopsy (SNB) is an important step in melanoma staging and prognostication. It is commonly performed for patients with intermediate thickness melanomas, based on clinicopathological features. However, only 20-25% of patients eventually demonstrate nodal involvement. The aim of this study was to evaluate whether tissue biomarkers with links to melanoma biology, together with clinicopathological parameters, could aid in the prediction of sentinel node involvement and improve selection of patients for SNB. In addition, we examined the role of these clinical or biological markers in disease outcome. Methods We collected a case-control cohort of 140 intermediate thickness (Breslow 0,9-4,0mm) melanoma patients with or without SNB involvement matched for age, gender, Breslow thickness and location. From this cohort, we tested the predictive value of common clinicopathological parameters (ulceration, mitotic count and tumor regression) and FMNL-2, ezrin and BRAF V600E immunoreactivity, for sentinel node involvement and survival. We further analyzed the correlations in the superficial spreading melanoma subtype. Results Based on our case control analysis, of the markers, BRAF V600E status (p = 0.010) and mitotic count (p = 0.036) correlated with SNB involvement. SNB status was a strong independent prognosticator for recurrence free survival (RFS p Conclusions These results demonstrate that BRAF immunohistochemistry could serve as a useful addition to a marker panel for selecting intermediate thickness melanoma patients for SNB.
Subject: MUTATIONS
BIOPSY
EZRIN
PATHWAYS
V600E
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0216043.pdf 1.473Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record